(S)-3-{6-[(tetrahydrofuran-3-yloxy)methyl]pyridin-2-ylmethyl}-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-ylamine | 1202402-47-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并嘧啶类
• 英文名称: (S)-3-{6-[(tetrahydrofuran-3-yloxy)methyl]pyridin-2-ylmethyl}-7-(5-methyl-2-furyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-5-ylamine
• 英文别名: 7-(5-methylfuran-2-yl)-3-[[6-[[(3R)-oxolan-3-yl]oxymethyl]pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine
• CAS: 1202402-47-8
• 化学式: C₂₀H₂₁N₇O₃
• 分子量: 407.432
• InChiKey: KURQKNMKCGYWRJ-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  127
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• Anti-CD73 antibodies
  申请人：CORVUS PHARMACEUTICALS, INC.

  公开号：US10793636B2

  公开（公告）日：2020-10-06

  Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same. The antibodies provided include amino acid substitution embodiments affecting the antibody glycosylation state. The antibodies provided herein are, inter alia, useful for the treatment of cancer and effective for inhibition of CD73 activity.

  本文特别提供了抗 CD73 抗体及其使用方法。所提供的抗体包括影响抗体糖基化状态的氨基酸取代实施例。本文提供的抗体尤其可用于治疗癌症并有效抑制 CD73 活性。
• Methods of treating cancer
  申请人：Corvus Pharmaceuticals, Inc.

  公开号：US10912776B2

  公开（公告）日：2021-02-09

  Provided herein are, inter alia, methods of treating cancer by administering to a subject a therapeutically effective amount of an adenosine-A2A(A2A) receptor antagonist or a combination of an adenosine-A2A(A2A) receptor antagonist and a programmed cell death protein 1(PD-1) signaling pathway inhibitor. Further provided are pharmaceutical compositions including an A2A receptor antagonist, a PD-1 signaling pathway inhibitor and a pharmaceutically acceptable excipient. Further provided are methods of detecting cellular effects, for example expression of pCREB, before, after or during adenosine receptor antagonist treatment.

  本文特别提供了通过向受试者施用治疗有效量的腺苷-A2A(A2A)受体拮抗剂或腺苷-A2A(A2A)受体拮抗剂与程序性细胞死亡蛋白1(PD-1)信号通路抑制剂的组合来治疗癌症的方法。还提供了包括 A2A 受体拮抗剂、PD-1 信号通路抑制剂和药学上可接受的赋形剂的药物组合物。还提供了在腺苷受体拮抗剂治疗之前、之后或期间检测细胞效应（例如 pCREB 的表达）的方法。
• 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
  申请人：Novartis AG

  公开号：US11185537B2

  公开（公告）日：2021-11-30

  The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Ra, Rb, Rx, R1, R2, X2, and q are as defined herein, and methods of making and using same.

  本公开提供了式(I′)化合物：或其药学上可接受的盐、水合物、溶液、原药、立体异构体或同系物，其中Ra、Rb、Rx、R1、R2、X2和q如本文所定义，以及制造和使用它们的方法。
• 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
  申请人：Novartis AG

  公开号：US11192877B2

  公开（公告）日：2021-12-07

  The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.

  本公开提供了一种式(I′)化合物： 或其药学上可接受的盐、水合物、溶液、原药、立体异构体或同系物，其中 Rx、X1、X2 和 R1 如本文所定义，以及制造和使用它们的方法。
• Antibody molecules to CD73 and uses thereof
  申请人：Novartis AG

  公开号：US11312783B2

  公开（公告）日：2022-04-26

  Antibody molecules that bind to CD73 are disclosed. The anti-CD73 antibody molecules can be used to treat, prevent and/or diagnose cancer.

  本研究公开了与 CD73 结合的抗体分子。抗 CD73 抗体分子可用于治疗、预防和/或诊断癌症。